List of Studies ( Metabolite:13,14-Dihydro-15-keto-PGF2alpha)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
---|---|---|---|---|---|---|---|
ST003049 | AN005000 | Plasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets | Blood | Human | University of Vienna | LC-MS | |
ST002977 | AN004889 | Offline Two-dimensional Liquid Chromatography-Mass Spectrometry for Deep Annotation of the Fecal Metabolome following Fecal Microbiota Transplant | Feces | Human | University of Michigan | LC-MS | |
ST002455 | AN004005 | Organism-Wide Analysis of Sepsis Reveals Mechanisms of Systemic Inflammation | Blood | Mouse | Sepsis | University of Chicago | LC-MS |
ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | LC-MS |
ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | LC-MS |
ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | LC-MS |
ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | LC-MS |
ST001783 | AN002894 | Performance of Three Differential Metabolites at Different TSS within 20 days | Blood | Mouse | Hebei medical university | LC-MS | |
ST001215 | AN002026 | Effect of Mirabegron Treatment on serum lipidome | Blood | Human | Joslin Diabetes Center | LC-MS | |
ST001214 | AN002025 | Lipidommics in the serum of human subjects | Blood | Human | Joslin Diabetes Center | LC-MS | |
ST001213 | AN002024 | Serum lipidomic profile of cold-exposed Ucp1cre/12-LOX KO mice | Blood | Mouse | Joslin Diabetes Center | LC-MS | |
ST001207 | AN002009 | Lipidomics in the serum of cold exposed mice treated with 12-LOX inhibitor LOXBlock-1 | Blood | Mouse | Joslin Diabetes Center | LC-MS | |
ST001206 | AN002008 | Effects of cold exposure on serum lipidomic in mice | Blood | Mouse | Joslin Diabetes Center | LC-MS | |
ST000917 | AN001497 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
ST000916 | AN001491 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
ST000915 | AN001485 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
ST000142 | AN000225 | H1299 13C-labeled Cell Study | Lung | Human | Cancer | University of Kentucky | LC-MS |
ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | LC-MS |
ST000046 | AN000079 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | LC-MS |
ST000004 | AN000004 | Lipidomics studies on NIDDK / NIST human plasma samples | Blood | Human | LIPID MAPS | LC-MS |